About Us

The Duke Human Vaccine Institute (DHVI) was selected to join the Collaborative Influenza Vaccine Innovation Centers (CIVICs) in all three components of the research program, which is funded by the National Institute of Allergic and Infectious Diseases (NIAID) through The Division of Microbiology and Infectious Diseases (DMID). The CIVICs program aims to improve the durability of seasonal influenza vaccines and develop a universal influenza vaccine through iterative vaccine design, pre-clinical animal studies, and early phase clinical trials.

The Duke CIVICS Program consists of multidisciplinary teams of investigators and their collaborators to support the research objectives laid out by the NIAID to design, manufacture, and test novel influenza vaccine candidates.

Back row (L to R): Mr. Chris Todd, Dr. Georgia Tomaras, Dr. Gregory Sempowski, Dr. Tony Moody, Dr. Thomas Denny, Ms. Hilary Bouton-Verville, Dr. Nicholas Heaton Front row (L to R): Dr. Matt Johnson, Dr. Chip Walter.